about
Defining professional pharmacy services in community pharmacy.Qualitative study on the implementation of professional pharmacy services in Australian community pharmacies using framework analysis.Providing patient care in community pharmacies in Australia.Mupirocin in the treatment of impetigo.Practice change in community pharmacy: quantification of facilitators.Exploring the role of pharmacists in outpatient dialysis centers: a qualitative study of nephrologist views.Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program.Implementation of medication review with follow-up in a Spanish community pharmacy and its achieved outcomes.The complexity of implementation factors in professional pharmacy services.Development and testing of two implementation tools to measure components of professional pharmacy service fidelity.The impact of a medication review with follow-up service on hospital admissions in aged polypharmacy patients.Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients.Renal nurses' views of the potential role of pharmacists in outpatient dialysis centres: a qualitative study.Facilitators for practice change in Spanish community pharmacy.Qualitative meta-synthesis of barriers and facilitators that influence the implementation of community pharmacy services: perspectives of patients, nurses and general medical practitionersCross-cultural adaptation of The Beliefs about Medicines Questionnaire into Portuguese.Clinical relevance of information in the Summaries of Product Characteristics for dose adjustment in renal impairment.Development of a theoretically based implementation protocol.Testing evidence routine practice: Using an implementation framework to embed a clinically proven asthma service in Australian community pharmacy.Patients' expectations of the role of the community pharmacist: Development and testing of a conceptual model.Model for the evaluation of implementation programs and professional pharmacy services.INPUT–OUTPUT ANALYSIS FOR BUSINESS PLANNING: A CASE STUDY OF THE UNIVERSITY OF SYDNEYLetter of response to correspondence regarding article “Defining professional pharmacy services in community pharmacy”Negative Clinical Outcomes Associated With Drug-Related Problems in Heart Failure (HF) Outpatients: Impact of a Pharmacist in a Multidisciplinary HF ClinicPharmaceutical care in community pharmacies: practice and research from around the world.Clinical investigation of topical antimicrobials in healthy volunteersTopical antimicrobial prophylaxis in minor woundsNon-prescription medicines: a process for standards development and testing in community pharmacyIs the inhaler technique associated with asthma control?Identifying masked uncontrolled hypertension in the community pharmacy setting[Priorization of facilitators for the implementation of medication review with follow-up service in Spanish community pharmacies through exploratory factor analysis]An international series on the integration of community pharmacy in primary health careEvaluation of a Collaborative Protocolized Approach by Community Pharmacists and General Medical Practitioners for an Australian Minor Ailments Scheme: Protocol for a Cluster Randomized Controlled TrialEconomic evaluations of pharmacist-led medication review in outpatients with hypertension, type 2 diabetes mellitus, and dyslipidaemia: a systematic reviewPrimary health care policy and vision for community pharmacy and pharmacists in Australia
P50
Q30429475-9B63AD79-E5C7-46E5-A2BE-055CB539FDBFQ36113780-8801E9F2-CF6B-45B1-94FE-93EE045A278CQ36284068-94027961-C7F8-40B3-BA29-CAD4A0C1530DQ36766132-A32CD633-2CB5-4766-92B0-D336B3439BCBQ37162876-74DC86D2-A104-4CBA-A15B-90B3ED5E0345Q38070624-7C503FF6-46B7-4C48-9E64-934CE7BDFFD4Q38379361-A9A01326-91B0-494D-8D75-F5A6FC49095DQ38514911-1AFB1E9A-5C5E-4D87-BA59-8EA18DAA0FE0Q38675432-B2780F45-8372-4FA9-A3A2-75964A9E54B8Q38681491-70D158A6-9B79-4ECC-9D80-188CC87A64BBQ38838250-EE035E2A-D3CA-4AFC-864A-0BD9675D8A84Q39028140-79FF7A57-3944-40A3-9CF3-B893EBD2E8EFQ39205706-BABA9A9D-E42F-41FF-9055-306D498B1C43Q40028888-1C45DD25-8245-4DA8-9759-AB5E67240BB0Q41582948-36400CD1-9092-47B4-9513-6C38F6AE12C5Q44019984-39984FDA-9AF7-4229-9F2E-5B83B0DA58D0Q44670585-60CC5FB6-7952-4A4E-A58A-00F629DAACB3Q46013798-FB044417-A9AD-44EB-B926-0053F8CE4373Q47839067-8200580C-8439-496E-A46C-AB303AC5C5BCQ50210752-A21E9C51-34FE-4472-9B94-5037A649DA86Q50794902-A0697C6C-E663-40BC-81B1-D91E41DA9300Q57206830-AAEE35C9-3660-466E-997A-4294BE9D0907Q60378732-4B8B3DAE-B8F7-4366-A8B7-AC8DE1D1B029Q60638657-DA72B3E6-4643-48AC-9957-C535149B2C97Q64923157-8D699107-C425-451E-8B99-C9C01B4B8014Q71978648-9D672FD7-615E-4C51-98B9-62FEE1ABD87CQ73361679-650000FA-D143-4C9C-A0F8-D104393D7025Q79859637-C2C033D8-0787-4142-B4F6-F179748829B0Q83378769-D43964D0-19F8-4F76-B97F-1F1AF5572B39Q86536795-A1D9F18A-ED3F-465A-94BD-00936E9356E9Q86916367-A02225CA-11D8-4264-890B-69729083CB8DQ91640441-EFCD3382-3583-474C-86BB-8DD536B844C7Q92537875-CB303CC0-DA0D-4143-A0E7-6E697C6D0B70Q92891776-0C8295CF-E0D7-4389-A273-1967FA4F5766Q96023945-ED44DBD4-3DA5-48E2-ADD9-0BD7E6C47D95
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Charlie Benrimoj
@ast
Charlie Benrimoj
@en
Charlie Benrimoj
@es
Charlie Benrimoj
@nl
type
label
Charlie Benrimoj
@ast
Charlie Benrimoj
@en
Charlie Benrimoj
@es
Charlie Benrimoj
@nl
prefLabel
Charlie Benrimoj
@ast
Charlie Benrimoj
@en
Charlie Benrimoj
@es
Charlie Benrimoj
@nl
P106
P31
P496
0000-0001-9768-7838